NICE Approves Kite’s Yescarta as NHS Treatment for Aggressive Forms of Blood Cancer
1 February 2023

NICE has announced the approval of Kite’s CAR-T cell therapy Yescarta, for the treatment of patients with r/r DLBCL and PMBCL, who have already had two or more lines of systemic therapy.
Recent Stories
8 June 2023
Eureka Therapeutics has received a
7 June 2023
UK-based independent innovation and technology
5 June 2023
BioCentriq launched their new LEAP™
2 June 2023
Nexcella, a subsidiary of Immix
POPULAR NEWS ITEMS
2 June 2023
denovoMATRIX GmbH announced the expansion
31 May 2023
Biotechnology Company Iovance Biotherapeutics has